Search Page

1

Cite

Share

Metabolism-guided design of short-acting calcium-sensing receptor antagonists.

Southers JA, Bauman JN, Price DA, Humphries PS, Balan G, Sagal JF, Maurer TS, Zhang Y, Oliver R, Herr M, Healy DR, Li M, Kapinos B, Fate GD, Riccardi KA, Paralkar VM, Brown TA, Kalgutkar AS. Southers JA, et al. Among authors: fate gd. ACS Med Chem Lett. 2010 May 13;1(5):219-23. doi: 10.1021/ml100058w. eCollection 2010 Aug 12. ACS Med Chem Lett. 2010. PMID: 24900198 Free PMC article.

Cite

Share

2

Cite

Share

Two-year carcinogenicity study in rats with a nonnucleoside reverse transcriptase inhibitor.

Nambiar PR, Morton D, Dochterman LW, Houle C, Thomford PJ, Fate G, Bailey SA, Finch GL. Nambiar PR, et al. Among authors: fate g. Toxicol Pathol. 2015 Apr;43(3):354-65. doi: 10.1177/0192623314544381. Epub 2014 Aug 13. Toxicol Pathol. 2015. PMID: 25122632

Cite

Share

3

Cite

Share

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.

Vourvahis M, McFadyen L, Nepal S, Valluri SR, Fang A, Fate GD, Wood LS, Marshall JC, Chan PLS, Nedderman A, Haynes J, Savage ME, Clark A, Smith KY, Heera J. Vourvahis M, et al. Among authors: fate gd. J Clin Pharmacol. 2019 Jan;59(1):139-152. doi: 10.1002/jcph.1306. Epub 2018 Sep 7. J Clin Pharmacol. 2019. PMID: 30192390 Free PMC article. Clinical Trial.

Cite

Share

4

Cite

Share

Biosynthesis and Identification of Metabolites of Maraviroc and Their Use in Experiments to Delineate the Relative Contributions of Cytochrome P4503A4 versus 3A5.

Tseng E, Fate GD, Walker GS, Goosen TC, Obach RS. Tseng E, et al. Among authors: fate gd. Drug Metab Dispos. 2018 May;46(5):493-502. doi: 10.1124/dmd.117.079855. Epub 2018 Feb 23. Drug Metab Dispos. 2018. PMID: 29475834

Cite

Share

5

Cite

Share

The distribution of esterases in the skin of the minipig.

Jewell C, Prusakiewicz JJ, Ackermann C, Payne NA, Fate G, Williams FM. Jewell C, et al. Among authors: fate g. Toxicol Lett. 2007 Sep 10;173(2):118-23. doi: 10.1016/j.toxlet.2007.07.004. Epub 2007 Jul 19. Toxicol Lett. 2007. PMID: 17719730

Cite

Share

6

Cite

Share

Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?

Kalgutkar AS, Fate G, Didiuk MT, Bauman J. Kalgutkar AS, et al. Among authors: fate g. Expert Rev Clin Pharmacol. 2008 Jul;1(4):515-31. doi: 10.1586/17512433.1.4.515. Expert Rev Clin Pharmacol. 2008. PMID: 24410554

Cite

Share

7

Cite

Share

Specificity of procaine and ester hydrolysis by human, minipig, and rat skin and liver.

Jewell C, Ackermann C, Payne NA, Fate G, Voorman R, Williams FM. Jewell C, et al. Among authors: fate g. Drug Metab Dispos. 2007 Nov;35(11):2015-22. doi: 10.1124/dmd.107.015727. Epub 2007 Jul 30. Drug Metab Dispos. 2007. PMID: 17664252

Cite

Share

8

Cite

Share

Multiple species metabolism of PHA-568487, a selective alpha 7 nicotinic acetylcholine receptor agonist.

Shilliday FB, Walker DP, Gu C, Fang X, Thornburgh B, Fate GD, Daniels JS. Shilliday FB, et al. Among authors: fate gd. Drug Metab Lett. 2010 Aug;4(3):162-72. Drug Metab Lett. 2010. PMID: 20642449

Cite

Share

9

Cite

Share

Hydrolysis of a series of parabens by skin microsomes and cytosol from human and minipigs and in whole skin in short-term culture.

Jewell C, Prusakiewicz JJ, Ackermann C, Payne NA, Fate G, Voorman R, Williams FM. Jewell C, et al. Among authors: fate g. Toxicol Appl Pharmacol. 2007 Dec 1;225(2):221-8. doi: 10.1016/j.taap.2007.08.002. Epub 2007 Aug 16. Toxicol Appl Pharmacol. 2007. PMID: 17889094

Cite

Share

10

Cite

Share

Using a tritiated compound to elucidate its preclinical metabolic and excretory pathways in vivo: exploring tritium exchange risk.

Shaffer CL, Gunduz M, Thornburgh BA, Fate GD. Shaffer CL, et al. Among authors: fate gd. Drug Metab Dispos. 2006 Sep;34(9):1615-23. doi: 10.1124/dmd.106.010934. Epub 2006 Jun 21. Drug Metab Dispos. 2006. PMID: 16790552

Cite

Share